%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2016-12-12T11:54:10-05:00
2016-12-12T11:54:11-05:00
2016-12-12T11:54:11-05:00
Adobe InDesign CC 2017 (Windows)
uuid:525cdb25-ddbc-40a7-b3ce-f508eb61fea6
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:942aff8b-36ed-cf49-b05a-7a24d347603a
proof:pdf
xmp.iid:c7363c18-fa4b-3e4f-9e3b-4e5aed40e6d5
xmp.did:4e38585b-65a2-6a49-a859-eef0dce40c18
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2016-12-12T11:54:10-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
18 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
56.231 0 Td
[(Clinical Briefs in P)18.1 (rimary Care)]TJ
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 373.76 Tm
(CLINICAL BRIEFS IN PRIMARY CARE)Tj
/T1_1 1 Tf
0 Tc 6 0 0 6 158.4884 373.76 Tm
(\231 )Tj
1.23 0 Td
( )Tj
-0.01 Tc -20.853 -1.167 Td
[(is published monthly by AHC Media, LLC. Copyright \251 2017)-9.9 ( )]TJ
0 -1.167 TD
[(AHC Media, LLC.)-10 ( )]TJ
/T1_2 1 Tf
8 0 0 8 40.75 349.76 Tm
(Physician Editor:)Tj
/T1_1 1 Tf
( Stephen Brunton, MD)Tj
/T1_2 1 Tf
0 -1.25 TD
(Assistant Editor:)Tj
/T1_1 1 Tf
( Jonathan Springston)Tj
/T1_2 1 Tf
0.01 Tw T*
(Editor)Tj
/T1_1 1 Tf
0 Tw (: Jill Drachenberg)Tj
6 0 0 6 40.75 315.76 Tm
[(This is an educational publication designed to present)-10 ( )]TJ
0 -1.167 TD
[(scientific information and opinion to health professionals,)-10 ( )]TJ
0 -1.167 TD
[(stimulate thought, and further investigation. It does not)-10 ( )]TJ
0 -1.167 TD
[(provide advice regarding medical diagnosis or treatment)-10 ( )]TJ
T*
(for any individual case. It is not intended for the layman.)Tj
0.01 Tc 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.025 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in)-25 ( )]TJ
-0.001 Tw T*
[(accordance with Accreditation Council for Continuing Medical)-25 ( )]TJ
0 Tw 0 -1.167 TD
[(Education guidelines, Dr. Brunton reports he is a retained)-25 ( )]TJ
0 -1.167 TD
[(consultant for Abbott Diabetes, Actavis, AstraZeneca, Becton)-25 ( )]TJ
T*
[(Dickinson, Boehringer Ingelheim, Cempra, Janssen, Lilly,)-25 ( )]TJ
0 -1.167 TD
[(Merck, Novo Nordisk, Sanofi, and Teva; he serves on the)-25 ( )]TJ
0 -1.167 TD
[(speakers bureau of AstraZeneca, Boehringer Ingelheim,)-25 ( )]TJ
T*
[(Janssen, Lilly, Novo Nordisk, and Teva. Dr. Kuritzky)-25 ( )]TJ
0 -1.167 TD
[(\(author\) is a retained consultant for and on the speakers)-25 ( )]TJ
0 -1.167 TD
[(bureau of Allergan, Daiichi Sankyo, Lilly, and Lundbeck.)-25 ( )]TJ
T*
[(Ms. Drachenberg and Mr. Springston report no financial)-25 ( )]TJ
0 -1.167 TD
(relationships relevant to this field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 165.734 338.51 re
S
/CS0 cs 0.1 scn
43.545 106.88 146.91 68.76 re
f
0.86 0.57 0 0.16 K
0.3 w 10 M
q 1 0 0 1 87.0262 146.0642 cm
0 0 m
78.677 0 l
S
Q
q 1 0 0 1 72.6205 139.0642 cm
0 0 m
42.017 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 48.0448 163.9401 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 48.0448 153.6641 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
-0.025 Tc 6 0 0 6 48.0448 146.6641 Tm
(Email Address: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
0.025 Tw (jspringston@reliaslearning.com)Tj
0 0 0 1 k
/GS0 gs
-0.01 Tc 0.01 Tw 0 -1.167 TD
(Website: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
4.096 0 Td
(AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
0 Tw -4.096 -1.917 Td
[(Address Correspondence to: AHC Media, One)-10 ( )]TJ
T*
[(Atlanta Plaza, 950 East Paces Ferry Road NE, Suite)-10 ( )]TJ
T*
[(2850, Atlanta, GA 30326.)-10 ( )]TJ
ET
/PlacedGraphic /MC0 BDC
EMC
q
81.64 55.558 70.72 32.442 re
W n
/GS1 gs
q 1 0 0 1 88.9838 74.8133 cm
0 0 m
-0.027 0 l
-0.163 -0.531 -0.313 -1.171 -0.463 -1.715 c
-1.171 -3.975 l
1.184 -3.975 l
0.463 -1.715 l
0.286 -1.157 0.136 -0.531 0 0 c
f
Q
q 1 0 0 1 107.4452 68.2239 cm
0 0 m
0.667 0 1.375 0.136 1.824 0.327 c
2.097 -0.994 l
1.702 -1.184 0.831 -1.402 -0.286 -1.402 c
-3.199 -1.402 -4.969 0.422 -4.969 3.227 c
-4.969 6.249 -2.859 8.073 -0.054 8.073 c
1.048 8.073 1.824 7.842 2.165 7.665 c
1.811 6.331 l
1.375 6.521 0.762 6.685 0.014 6.685 c
-1.852 6.685 -3.199 5.514 -3.199 3.308 c
-3.199 1.28 -2.028 0 0 0 c
-6.127 -1.252 m
-7.801 -1.252 l
-7.801 2.791 l
-11.681 2.791 l
-11.681 -1.252 l
-13.356 -1.252 l
-13.356 7.924 l
-11.681 7.924 l
-11.681 4.248 l
-7.801 4.248 l
-7.801 7.924 l
-6.127 7.924 l
h
-16.174 -1.252 m
-17.005 1.348 l
-19.905 1.348 l
-20.694 -1.252 l
-22.423 -1.252 l
-19.483 7.924 l
-17.345 7.924 l
-14.364 -1.252 l
h
-25.805 -12.253 31.616 31.616 re
-25.805 19.363 m
f
Q
q 1 0 0 1 125.1715 70.7154 cm
0 0 m
-0.054 1.185 -0.123 2.614 -0.109 3.853 c
-0.15 3.853 l
-0.449 2.736 -0.831 1.498 -1.239 0.34 c
-2.587 -3.635 l
-3.866 -3.635 l
-5.092 0.286 l
-5.446 1.457 -5.772 2.709 -6.018 3.853 c
-6.045 3.853 l
-6.086 2.655 -6.14 1.198 -6.208 -0.055 c
-6.413 -3.744 l
-7.978 -3.744 l
-7.365 5.432 l
-5.16 5.432 l
-3.962 1.743 l
-3.635 0.667 -3.349 -0.422 -3.118 -1.443 c
-3.077 -1.443 l
-2.832 -0.449 -2.519 0.681 -2.165 1.756 c
-0.899 5.432 l
1.28 5.432 l
1.811 -3.744 l
0.177 -3.744 l
h
f
Q
q 1 0 0 1 132.7822 70.9877 cm
0 0 m
0.014 0.613 -0.259 1.62 -1.375 1.62 c
-2.41 1.62 -2.846 0.681 -2.914 0 c
h
-2.914 -1.171 m
-2.873 -2.369 -1.947 -2.886 -0.871 -2.886 c
-0.095 -2.886 0.449 -2.764 0.966 -2.587 c
1.211 -3.73 l
0.64 -3.975 -0.15 -4.152 -1.103 -4.152 c
-3.254 -4.152 -4.52 -2.832 -4.52 -0.803 c
-4.52 1.035 -3.404 2.764 -1.28 2.764 c
0.871 2.764 1.579 0.994 1.579 -0.463 c
1.579 -0.776 1.552 -1.021 1.525 -1.171 c
h
f
Q
q 1 0 0 1 140.1476 70.8379 cm
0 0 m
0 0.136 -0.014 0.313 -0.041 0.449 c
-0.191 1.089 -0.721 1.62 -1.484 1.62 c
-2.559 1.62 -3.158 0.667 -3.158 -0.558 c
-3.158 -1.783 -2.559 -2.668 -1.497 -2.668 c
-0.817 -2.668 -0.218 -2.205 -0.054 -1.484 c
-0.014 -1.334 0 -1.171 0 -0.994 c
h
1.675 5.8 m
1.675 -2.001 l
1.675 -2.682 1.702 -3.417 1.729 -3.866 c
0.245 -3.866 l
0.163 -2.818 l
0.136 -2.818 l
-0.259 -3.553 -1.062 -4.016 -2.015 -4.016 c
-3.608 -4.016 -4.86 -2.668 -4.86 -0.626 c
-4.874 1.593 -3.485 2.914 -1.892 2.914 c
-0.98 2.914 -0.327 2.546 -0.027 2.056 c
0 2.056 l
0 5.8 l
h
f
Q
143.619 73.602 1.675 -6.63 re
143.619 66.971 m
145.403 75.453 m
145.403 74.963 145.036 74.555 144.45 74.555 c
143.892 74.555 143.524 74.963 143.524 75.453 c
143.524 75.971 143.906 76.365 144.464 76.365 c
145.036 76.365 145.39 75.971 145.403 75.453 c
f
q 1 0 0 1 150.6175 70.2117 cm
0 0 m
-1.184 0.014 -2.315 -0.231 -2.315 -1.239 c
-2.315 -1.892 -1.892 -2.192 -1.361 -2.192 c
-0.681 -2.192 -0.204 -1.756 -0.041 -1.28 c
0 -1.157 0 -1.035 0 -0.912 c
h
1.634 -1.647 m
1.634 -2.246 1.661 -2.832 1.743 -3.24 c
0.231 -3.24 l
0.109 -2.505 l
0.068 -2.505 l
-0.327 -3.022 -1.021 -3.39 -1.892 -3.39 c
-3.226 -3.39 -3.975 -2.423 -3.975 -1.416 c
-3.975 0.245 -2.492 1.103 -0.041 1.089 c
-0.041 1.198 l
-0.041 1.634 -0.218 2.355 -1.389 2.355 c
-2.042 2.355 -2.723 2.151 -3.172 1.865 c
-3.499 2.954 l
-3.009 3.254 -2.151 3.54 -1.103 3.54 c
1.021 3.54 1.634 2.192 1.634 0.735 c
h
f
Q
Q
/CS0 CS 1 SCN
1 w
/GS1 gs
q 1 0 0 1 36 578.6998 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 36 543.5248 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
/T1_3 1 Tf
0.01 Tc -0.009 Tw 9 0 0 9 36 737.0496 Tm
[(prescribed reduced-dose NOACs matched)10 ( )]TJ
0 Tw 0 -1.219 TD
(labeling criteria for such dose reduc)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
[(tion. It may have been that concern over)10 ( )]TJ
T*
[(bleeding risk prompted prescribers to)10 ( )]TJ
T*
[(choose dose reduction; however)111 (, bleeding)9.9 ( )]TJ
0 -1.219 TD
[(rates even within this group of patients)10 ( )]TJ
0 -1.219 TD
[(receiving reduced-dose NOAC actually)10 ( )]TJ
T*
[(were higher than had been seen in clinical)10 ( )]TJ
0 -1.219 TD
[(trials of NOACs.)10 ( )]TJ
0 -2.439 TD
[(How dose adjustment based on clinician)10 ( )]TJ
0 -1.219 TD
[(judgment, as opposed to speci\037c FDA)10 ( )]TJ
T*
[(labeling, will affect long-term outcomes)10 ( )]TJ
0 -1.219 TD
[(remains to be determined. )10 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 144.2417 594.3748 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 36 564.6998 Tm
[(Placebo for Osteoarthritis)-4.9 ( )]TJ
0.005 Tw 0 -1.155 TD
[(P)35.7 (ain)]TJ
/TT1 1 Tf
0 Tc 0 Tw 9 0 0 9 36 525.5498 Tm
[(SOURCE: Dieppe P)239.1 (, Goldingay S, Greville-)]TJ
0 -1.219 TD
(Harris M. The power and value of placebo and )Tj
0 -1.219 TD
(nocebo in painful osteoarthritis. )Tj
/TT2 1 Tf
12.21 0 Td
(Osteoarthritis )Tj
-12.21 -1.219 Td
(Cartilage)Tj
/TT1 1 Tf
3.279 0 Td
( 2016;24:1850-1857.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 35.7927 461.8499 Tm
(T)Tj
/T1_3 1 Tf
0.01 Tc 9 0 0 9 54.678 472.6499 Tm
(erminology about placebo, accord)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.2 TD
[(ing to Dieppe et al, might be more)10 ( )]TJ
-2.075 -1.219 Td
[(useful if divided into placebo response)10 ( )]TJ
0 -1.219 TD
[(\(\223a change seen in response to a sham)10.1 ( )]TJ
0 -1.219 TD
[(intervention\224\) and placebo effect \(\223the)10 ( )]TJ
T*
[(difference between doing nothing ... and)10 ( )]TJ
T*
[(giving a sham treatment\224\). The authors)9.9 ( )]TJ
0 -1.219 TD
[(chose to focus on the symptomatic)10 ( )]TJ
ET
/GS1 gs
q 1 0 0 1 214.008 436.1178 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 214.008 400.9463 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9 0 0 9 214.008 737.0496 Tm
[(improvements that can occur for patients)10 ( )]TJ
0 -1.219 TD
[(simply as a result of an encounter with a)10 ( )]TJ
T*
(health professional.)Tj
0 -2.438 TD
[(By comparing pain reduction achieved in)10 ( )]TJ
-0.002 Tw 0 -1.219 TD
[(placebo groups of randomized, controlled)10 ( )]TJ
0 Tw 0 -1.219 TD
[(osteoarthritis trials with treatment arms)10 ( )]TJ
0 -1.219 TD
[(that received no treatment \(not even)10 ( )]TJ
0 -1.219 TD
[(placebo\), the authors determined that an)10 ( )]TJ
0 -1.219 TD
(effect size of about 0.5 is seen with pla)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
[(cebo, comparable to that seen with many)10 ( )]TJ
0 -1.219 TD
[(\223active\224 interventions. Context also may)9.9 ( )]TJ
T*
[(be important. For instance, injection)9.9 ( )]TJ
T*
(placebos were particularly powerful.)Tj
0 -2.438 TD
[(The physiologic underpinnings of)10 ( )]TJ
0 -1.219 TD
[(placebo response for pain indicate it is)10 ( )]TJ
T*
[(not \223imaginary)91.9 (.\224 For instance, the pain)10 ( )]TJ
T*
[(reduction of placebo can be blocked by)10 ( )]TJ
T*
(pre-administration of naloxone, suggest)Tj
0 Tc (-)Tj
0.01 Tc T*
[(ing that such responses may be re\036ective)10 ( )]TJ
T*
[(of activation of endogenous endorphins.)10 ( )]TJ
0 -2.438 TD
(The authors concluded that positive pla)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
[(cebo response from patients occurs most)10 ( )]TJ
0 -1.219 TD
[(fruitfully when patients feel safe, calm,)9.9 ( )]TJ
T*
[(and validated by their clinician. )10 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 344.5162 451.7894 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 214.008 422.1178 Tm
[(New T)175 (ools for Glucose)-4.8 ( )]TJ
0 Tc 9.438 0 Td
( )Tj
-0.005 Tc 0.005 Tw -9.438 -1.155 Td
(Monitoring)Tj
/TT1 1 Tf
0 Tc 0 Tw 9 0 0 9 214.008 382.9747 Tm
(SOURCE: Bolinder J, Antuna R, Geelhoed-)Tj
T*
[(Duijvestijn P)239.1 (, et al. Novel glucose-sensing )]TJ
T*
(technology and hypoglycaemia in type 1 diabe)Tj
(-)Tj
T*
(tes: A multicentre, non-masked, randomised, )Tj
T*
(controlled trial. )Tj
/TT2 1 Tf
5.985 0 Td
[(L)17.6 (ancet)]TJ
/TT1 1 Tf
( 2016;388:2254-2263.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 213.8007 308.317 Tm
(T)Tj
/T1_3 1 Tf
0.005 Tc 9 0 0 9 232.5344 319.117 Tm
[(he inconvenience of frequent \037nger)55 (-)]TJ
0 -1.2 TD
[(stick testing to assess control of)5 ( )]TJ
-2.058 -1.219 Td
[(diabetes is particularly problematic for)5 ( )]TJ
0 -1.219 TD
[(type 1 diabetics. The FreeStyle Libre)5 ( )]TJ
T*
[(\(trade name\) is a sensor the size of a)5 ( )]TJ
T*
[(human hair that is inserted in the skin of)5.1 ( )]TJ
0 -1.219 TD
[(the upper arm and attached to a patch)5 ( )]TJ
0 -1.219 TD
[(that records glucose readings over eight)5 ( )]TJ
0 -1.219 TD
(hours. The reading device can be down)Tj
0 Tc (-)Tj
0.005 Tc T*
[(loaded and has the capacity to store up)5 ( )]TJ
0 -1.219 TD
[(to 90 days of readings. Does the FreeStyle)5.1 ( )]TJ
0 -1.219 TD
[(Libre outperform traditional \037ngerstick)5 ( )]TJ
-0.005 Tw T*
(methodologies?)Tj
0 Tw 0 -2.438 TD
[(T)98 (o test this hypothesis, Bolinder et al ran)]TJ
0 Tc (-)Tj
0.005 Tc 0 -1.219 TD
(domized participants with already well-)Tj
T*
[(controlled type 1 diabetes \(n = 328\) to use)5.1 ( )]TJ
T*
[(the \223\036ash glucose monitoring system\224 or)5.1 ( )]TJ
T*
[(typical \037nger)55 (-stick monitoring. The pri)]TJ
0 Tc (-)Tj
0.005 Tc T*
[(mary outcome of the trial was amount of)5 ( )]TJ
T*
[(time in hypoglycemia during six months)5 ( )]TJ
T*
[(of follow-up. T)37 (ime in hypoglycemia was)5 ( )]TJ
T*
[(reduced by 38% with the Freestyle Libre)5 ( )]TJ
T*
(device, compared to \223traditional\224 meth)Tj
0 Tc (-)Tj
0.005 Tc T*
[(ods. A small number of participants \(n =)5 ( )]TJ
0 -1.219 TD
[(10\) experienced local reactions at the site)5 ( )]TJ
ET
/GS1 gs
q 1 0 0 1 392.016 677.4918 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 392.016 642.3203 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9 0 0 9 392.016 737.0496 Tm
[(of insertion of the sensor)111 (.)]TJ
0 -2.438 TD
(The device recently received FDA ap)Tj
0 Tc (-)Tj
0.005 Tc 0 -1.219 TD
[(proval. A FreeStyle Libre \223starter kit\224)5 ( )]TJ
0 -1.219 TD
[(currently is advertised at $359. )-5 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 519.0769 693.1633 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 392.016 663.4918 Tm
[(Dietary Supplement T)175 (rends,)-4.9 ( )]TJ
0.005 Tw 0 -1.155 TD
(1999-2012)Tj
/TT1 1 Tf
0 Tc 0 Tw 9 0 0 9 392.016 624.3487 Tm
[(SOURCE: K)17.5 (antor ED, R)17.5 (ehm CD, Du M, et al. )]TJ
0 -1.219 TD
[(T)155.7 (rends in dietary supplement use among US )]TJ
T*
(adults from 1999-2012. )Tj
/TT2 1 Tf
9.395 0 Td
(JAMA)Tj
/TT1 1 Tf
( 2016;316:1464-)Tj
-9.395 -1.219 Td
(1474.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 392.6823 560.6625 Tm
(A)Tj
/T1_3 1 Tf
0.005 Tc 9 0 0 9 411.7269 571.4625 Tm
[(ccording to results from in-home)5 ( )]TJ
0 Tc 14.61 0 Td
( )Tj
0.005 Tc -14.61 -1.2 Td
[( interviews with 37,859 U.S. adults,)5 ( )]TJ
-2.19 -1.219 Td
[(52% reported use of a supplement)5 ( )]TJ
T*
[(within the 30 days prior to the interview)92 (.)5 ( )]TJ
T*
(Included under the canopy of \223supple)Tj
0 Tc (-)Tj
0.005 Tc T*
[(ments\224 were multivitamins, \037sh oil, and)5 ( )]TJ
T*
[(individual supplements \(such as vitamin)5 ( )]TJ
T*
[(D\). Of concern \(depending on your)5 ( )]TJ
T*
(personal p)Tj
-0.005 Tw (hilosophical-scienti\037c)Tj
0 Tw [( position)5 ( )]TJ
0 -1.219 Td
[(on the issue\), the use of supplements has)5 ( )]TJ
T*
[(remained essentially stable during the)5.1 ( )]TJ
T*
[(1999-2012 interval.)5 ( )]TJ
0 -2.438 TD
[(Although some major players)5 ( )]TJ
0 -1.219 TD
[(have declined over the past decade)5 ( )]TJ
0 -1.219 TD
[(\(multivitamin/multimineral use decreased)5 ( )]TJ
0 -1.219 TD
[(from 37% to 31%\), others have increased)5 ( )]TJ
0 -1.219 TD
[(substantially: \037sh oil use increased from)5 ( )]TJ
0 -1.219 TD
[(1.3% in 1999 to 12% in 2012, and)5 ( )]TJ
0 -1.219 TD
[(vitamin D increased from 5.3% to 19%.)5 ( )]TJ
0 -1.219 TD
[(The authors reported that approximately)5 ( )]TJ
T*
[(25% of supplement use had been)5 ( )]TJ
T*
[(recommended by a healthcare provider)111 (.)5 ( )]TJ
0 -2.438 TD
[(W)18 (ith the exception of folate)5.1 ( )]TJ
0 -1.219 TD
[(supplementation for women, support)5 ( )]TJ
T*
[(for the bene\037ts of supplements, in the)5 ( )]TJ
T*
[(absence of prede\037ned de\037ciency)92 (, is scant.)]TJ
0 -2.438 TD
[(The item that provided me that greatest)5 ( )]TJ
0 -1.219 TD
[(reason for pause was not in the article)5.1 ( )]TJ
T*
[(itself but an editorial about this article in)5 ( )]TJ
T*
(the same issue of )Tj
/T1_4 1 Tf
-0.005 Tw (JAMA)Tj
/T1_3 1 Tf
0 Tw [(, which I believe)5 ( )]TJ
T*
[(deserves to be quoted in full \(reader)5 ( )]TJ
0 -1.219 TD
(discretion is advised\): \223... even after high-)Tj
0 -1.219 TD
[(quality studies that show no meaningful)5 ( )]TJ
0 -1.219 TD
[(clinical differences between supplements)5.1 ( )]TJ
0 -1.219 TD
(and placebos are published, the law pro)Tj
0 Tc (-)Tj
0.005 Tc 0 -1.219 TD
[(vides [supplement] manufacturers latitude)5 ( )]TJ
0 -1.219 TD
[(to continue advertising their products)5.1 ( )]TJ
0 -1.219 TD
[(based on earlier)111 (, low-quality data. For)5 ( )]TJ
0 -1.219 TD
[(example, Ginkgo biloba continues to be)5 ( )]TJ
0 -1.219 TD
[(sold \221to support mental sharpness\222 despite)5 ( )]TJ
T*
[(a large, high-quality)92 (, NIH-funded study)5 ( )]TJ
T*
[(that found evidence to the contrary)92 (.\224)]TJ
0 -2.438 TD
[(I am already reasonably supple. In the)5 ( )]TJ
0 -1.219 TD
[(absence of strong evidence, I will continue)5 ( )]TJ
T*
(to eschew supplements. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 489.0529 44.9999 Tm
<0084>Tj
ET
endstream
endobj
24 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
10 0 obj
<>
endobj
23 0 obj
<>
endobj
25 0 obj
<>stream
application/postscript
AHCmedia(New)_3 tag options_11.8.13
Travis
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
xmp.did:bdec626a-762d-6946-8d41-56d8de9e49a7
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
xmp.did:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
converted
from application/pdf to <unknown>
saved
xmp.iid:D27F11740720681191099C3B601C4548
2008-04-17T14:19:15+05:30
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F1174072068118D4ED246B3ADB1C6
2008-05-15T16:23:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FA7F1174072068118D4ED246B3ADB1C6
2008-05-15T17:10:45-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:EF7F117407206811A46CA4519D24356B
2008-05-15T22:53:33-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F07F117407206811A46CA4519D24356B
2008-05-15T23:07:07-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BDDDFD38D0CF24DD
2008-05-16T10:35:43-07:00
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F117407206811BDDDFD38D0CF24DD
2008-05-16T10:40:59-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to <unknown>
saved
xmp.iid:FA7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:26:55-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FB7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:01-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FC7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:20-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FD7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:30:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FE7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:31:22-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B233668C16206811BDDDFD38D0CF24DD
2008-05-16T12:23:46-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B333668C16206811BDDDFD38D0CF24DD
2008-05-16T13:27:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B433668C16206811BDDDFD38D0CF24DD
2008-05-16T13:46:13-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F11740720681197C1BF14D1759E83
2008-05-16T15:47:57-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F87F11740720681197C1BF14D1759E83
2008-05-16T15:51:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F11740720681197C1BF14D1759E83
2008-05-16T15:52:22-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FA7F117407206811B628E3BF27C8C41B
2008-05-22T13:28:01-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FF7F117407206811B628E3BF27C8C41B
2008-05-22T16:23:53-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:07C3BD25102DDD1181B594070CEB88D9
2008-05-28T16:45:26-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:F87F1174072068119098B097FDA39BEF
2008-06-02T13:25:25-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BB1DBF8F242B6F84
2008-06-09T14:58:36-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F117407206811ACAFB8DA80854E76
2008-06-11T14:31:27-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:0180117407206811834383CD3A8D2303
2008-06-11T22:37:35-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811818C85DF6A1A75C3
2008-06-27T14:40:42-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:2759AC6B4FA8E211B099CEB363CBA397
2013-04-18T13:43:03-04:00
Adobe Illustrator CS4
/
saved
xmp.iid:5E11DEB5A8216811822A8C4A5BB13D00
2014-01-03T17:39:31-05:00
Adobe Illustrator CS6 (Macintosh)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
2014-01-06T10:41:10-05:00
Adobe Illustrator CC (Windows)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
3.584901
1.584901
Inches
Black
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE 288 U
SPOT
100.000000
CMYK
100.000000
67.000002
0.000000
23.000000
PANTONE 313 C
SPOT
100.000000
CMYK
100.000000
0.000000
8.000200
13.000500
PANTONE 313 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.000000
13.000000
PANTONE 187 U
SPOT
100.000000
CMYK
0.000000
100.000000
78.999299
19.999699
PANTONE 309 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.999600
72.000098
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 10.01
endstream
endobj
11 0 obj
<>
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
12 0 obj
<>
endobj
22 0 obj
<>
endobj
13 0 obj
<>
endobj
15 0 obj
<>
endobj
16 0 obj
<>
endobj
43 0 obj
<>
endobj
44 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
45 0 obj
<>stream
HtU TSW['}M*HqCD4PdZZQRZZuu\pV-
=ͨ0{w ;,3Bg}C{DIE%G ȭ,Wj{{ $Yk~ɬ"u (hVaM~nLR,9yٺCq%ݤ* |, (xPPT^ms!aIS^Xo2 8
^5/(oln"in|IqY
f}Ljk)[x2`|̅ ˗qq` 7ĉX=&1fQ;Qh<$[l~DTfemckg W8*]\=<}|Uj A 9,*zẍFeLqc%0q)ISMf[ڴg\]^s+.)_V^QYU]/YbWTfodc[6~ٶ;v6Ů{ZUo?C'v3mgϝpw|;nܼu;w.
<&&e
XY5[s*@کh$`Md!1 e>,%sm|c,E0L?!n1569KwxXpÔ9fɃDTrx[E
qDh;>8`
VSA3|;xЅg DZh;.ׯ'؈p#zh.FcKM% $4\4Q #Ahqgn;O|*\^,B89?sm*d3rKcLGXVsq`zt>ZFkq(X%6pAHܑK˸.ɬVHZ/#pD"w<茪ƈ`FGluvkS6`\"j:łGKHi絰&\A2Wl~5,4H$֔Ni-ԫ*^z$
!?ߏ0Y>4=f/V*c9:}4B:xX\#YoW:l2%kO1M/zy^{gGC&'kUˊ'--I>.>N|c/6ө,WI)ܛB
B݆0;PBW+xϾzK(J1eUe`T-!XK!A1ǘ0
w9T駌#zkz2]u`k/4Z'&̯=Pv&ud&zb")6V!ݎ
_o/OwWg'B`ogkc%{]k7㲫mGwegy25Vj)-nevZ~^+5c3}[KƮZ|Yθً>hϺ'FGL#u/)&_A|LG(*bk|!:
reLwe3}
S0Xو^N
7w_MРPoS\6km+o3
CȬ#FrrK`\.~܂
Λ۸h3[|@;[ǧ?Ɏ~RX;56cmlԓupOn=,||(TC?y3fϸqpy?;:/gνZi')'蜬'nh `2m:R{d%-,6("^DVqJb5rb"psd$h&o/*,k[RYi+
&c ץ6
a*{{4MaĺB!F< ֳM. t'ĎDD^4 ƨ8n)NoԊ`a5g٣aF-IzGzL
_&]IX>M .NJ'Y8N'¸Ӥ۸RqӞƑv}S{._:8}%A.cMr]ҁJZ{=Goz_:`6 іd3J~8C jR5mVpHR Ng@N$`{X}ukΗFnZ=5v8҃IXV0ZbSx7z0HE[E`b